EGFR and non-small cell lung carcinoma: We observed that, similarly to its effect in SK-BR-3, the dual inhibition of EGFR and ErbB2 by lapatinib was able to decrease SOCE amplitude in non-small cell lung carcinoma cells (i.e. A549), epidermoid carcinoma cells (i.e. A431) and also in an embryonic cell line (i.e. NIH-3T3) (Figure 7).